Shots:
- InnoCare has reported a P-III trial assessing the efficacy, safety & tolerability of fadeucravacitinib (ICP-488) vs PBO in pts with moderate-to-severe plaque psoriasis
- Trial met its 1EP with statistically significant & clinically meaningful improvement, while also achieving multiple 2EPs, demonstrating consistent efficacy across measures; data to be presented & published in the future
- Fadeucravacitinib is an oral, selective TYK2 allosteric inhibitor that blocks IL-23, IL-12, type I IFN, & other inflammatory cytokine signaling. It is being developed for psoriasis, cutaneous lupus erythematosus (CLE), & Sjögren’s syndrome
Ref: Globenewswire | Image: InnoCare | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
